Full Text View
Tabular View
Study Results
Related Studies
Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471AM1)(COMPLETED)
This study has been completed.
Study NCT00081770   Information provided by Schering-Plough
First Received: April 20, 2004   Last Updated: September 24, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatitis C, Chronic
Additional conditions recognized in this trial
Hepatitis
Hepatitis C
Hepatitis, Chronic
More general conditions related to this trial
Digestive System Diseases
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
REBETOL (ribavirin; SCH 18908)
PEGASYS (peginterferon alfa-2a)
COPEGUS (ribavirin)
Additional drug interventions recognized in this trial
Interferon Alfa-2b
Peginterferon alfa-2a
Peginterferon alfa-2b
Ribavirin
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antimetabolites
Antineoplastic Agents
Antiviral Agents
Growth Inhibitors
Growth Substances
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Schering-Plough


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services